Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
about
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel diseaseBiosimilars in paediatric inflammatory bowel diseaseNon-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
P2860
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Switching from reference infli ...... el disease: 12 months results.
@en
Switching from reference infli ...... el disease: 12 months results.
@nl
type
label
Switching from reference infli ...... el disease: 12 months results.
@en
Switching from reference infli ...... el disease: 12 months results.
@nl
prefLabel
Switching from reference infli ...... el disease: 12 months results.
@en
Switching from reference infli ...... el disease: 12 months results.
@nl
P2093
P2860
P50
P1476
Switching from reference infli ...... el disease: 12 months results.
@en
P2093
Angel Caunedo Álvarez
Antonio Benítez Roldán
Belen Maldonado Pérez
Dina Chaaro Benallal
Gabriel Ramirez
Luisa Castro Laria
Miguel Angel Calleja-Hernández
Raul Perea Amarillo
Vicente Merino
P2860
P304
P356
10.1097/MEG.0000000000000953
P577
2017-09-08T00:00:00Z